STSS Aspire Heal Task Order 10

STSS Aspire Heal 任务令 10

• 批准号: 10950010
• 金额: $ 334.71万
• 依托单位: AXLE INFORMATICS, LLC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-18 至 2025-09-17
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10950010
• 关键词: STSS; Aspire; Heal; Task; Order

Over 25 million people in the United States experience pain every day (2012 National Health Interview Survey data) and need safe, addiction-free treatments to alleviate their suffering. This clinical demand is of tremendous importance given that overprescribing and abuse of opioids for managing acute and chronic pain has fueled the current epidemic of opioid use disorder and overdose deaths, and the effectiveness of opioids for long-term pain management is being questioned. Safe, effective, and non-addictive drugs (small molecules and biologics) to treat pain, mitigate addiction and reverse overdose are key to addressing the opioid crisis that has only worsened following the COVID-19 pandemics. Given failures and limitations of previous drug development efforts, drugs that recognize novel targets, have novel structures, and can be identified in human-based, physiologically relevant in vitro systems are needed. In 2018 NCATS by releasing NCATS ASPIRE Design Challenges, which solicited design ideas from the broader scientific community to address areas of the preclinical drug discovery process related to non-addictive pain treatment that could be accelerated by the introduction of new technologies related to: • Integrated Chemistry Databases • Electronic Synthetic Chemistry Portals • Predictive Algorithms • Biological Assays • Integrated Solutions of the above aspects In 2020, NCATS followed up with the ASPIRE Reduction-to-Practice Challenge, in which extramural researchers and innovators formed collaborative teams to deliver fully functioning prototypes of a non-addictive analgesics drug discovery platform that incorporated all the challenge topics from the design challenges (Integrated Chemistry Databases, Electronic Synthetic Chemistry Portals, Predictive Algorithms, Biological Assays). The Purdue University Team (PI: Gaurav Chopra) and the CiBots, Inc. Team (PI: Babak Esmaeli-Azad) garnered the grand prize and the runner-up prizes, respectively. We are now seeking to harness the array of technologies developed during the 2020 NCATS ASPIRE Reduction-to-Practice Challenge to build a non-traditional, merged, “super-team” of all expertise necessary to (1) complete integration of the two complementary platforms and (2) enhance the unified platform’s capability and rapidly deliver new analgesics drug candidates with safe and improved properties.

在美国，每天有超过 2500 万人遭受疼痛（2012 年全国健康访谈调查数据），需要安全、无成瘾的治疗来减轻他们的痛苦。 鉴于用于治疗急性和慢性疼痛的阿片类药物的过度处方和滥用加剧了当前阿片类药物使用障碍和过量死亡的流行，并且阿片类药物用于长期疼痛管理的有效性受到质疑，这一临床需求非常重要。用于治疗疼痛、减轻成瘾和逆转用药过量的安全、有效和非成瘾药物（小分子和生物制剂）是解决阿片类药物危机的关键，该危机在 COVID-19 大流行后只会进一步恶化。鉴于先前药物开发工作的失败和局限性，需要识别新靶点、具有新结构并且可以在基于人体的、生理相关的体外系统中识别的药物。 2018 年，NCATS 发布了 NCATS ASPIRE 设计挑战赛，该挑战赛向更广泛的科学界征求设计理念，以解决与非成瘾性疼痛治疗相关的临床前药物发现过程，通过引入与以下相关的新技术可以加速这一过程： • 综合化学数据库 • 电子合成化学门户 • 预测算法 • 生物测定 • 以上方面的综合解决方案 2020 年，NCATS 发起了 ASPIRE Reduction-to-Practice Challenge，校外研究人员和创新者组成了协作团队，提供功能齐全的非成瘾性镇痛药物发现平台原型，该平台包含了设计挑战中的所有挑战主题（集成化学数据库、电子合成化学门户、预测算法、生物测定）。普渡大学团队（PI：Gaurav Chopra）和 CiBots, Inc. 团队（PI：Babak Esmaeli-Azad）分别获得大奖和亚军。我们现在正在寻求利用 2020 年 NCATS ASPIRE Reduction-to-Practice Challenge 期间开发的一系列技术，建立一个非传统的、合并的、由所有必要专业知识组成的“超级团队”，以 (1) 完成两个互补平台的整合，以及 (2) 增强统一平台的能力，并快速提供具有安全和改进特性的新止痛候选药物。